Pharmaceutical Raw Material CAS 151767-02-1 Montelukast Sodium Powder

Description
Montelukast Sodium is a potent, selective, anti-inflammatory CysLT1 receptor antagonist (IC50 < 5nM) with no appreciable affecton the CysLT2 receptor. In rat colitis Montelukast Sodium has demonstrated the ability to increase PGE2 (Prostaglandin E2 - sc-201225) production and lower COX-2 expression. Inhibition is competitive with respect to leukotrienes - particularly LTD4, a biologically active mediator that plays an important role in the control of several biochemical pathways involving pulmonary and immune system function.Because of its method of operation, it is not useful for the treatment of acute asthma attacks. Again because of its very specific mechanism of action, it does not interact with other asthma medications such as theophylline.Another leukotriene receptor antagonist is zafirlukast (Accolate), taken twice daily. Zileuton (Zyflo), an asthma drug taken four times per day, blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway.

Certificate of Analysis

Function & Application:

Montelukastis a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.Montelukast comes as a tablet, a chewable tablet, flash tablet and granules to take by mouth.Montelukast is usually taken once a day with or without food.Montelukast is a CysLT1 antagonist; it blocks the action of leukotriene D4 (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene and results in less inflammation.

Related Products